Doxorubicin Market By Application (Ovarian, Multiple Myeloma, Kaposi Sarcoma, Leukemia, Bone Sarcoma, Breast, Endometrial, Gastric, Liver, Kidney, Other Cancers) And Segment Forecasts, 2018 - 2024Report

Doxorubicin Market By Application (Ovarian, Multiple Myeloma, Kaposi Sarcoma, Leukemia, Bone Sarcoma, Breast, Endometrial, Gastric, Liver, Kidney, Other Cancers) And Segment Forecasts, 2018 - 2024

  • Published Date: Nov 2016
  • Report ID: GVR-1-68038-288-4
  • Number of Pages: 84
  • Format: Electronic (PDF)
  • Historical Data: 2013 - 2014

Table of Contents

Chapter 1 Executive Summary
Chapter 2 Market Snapshot
Chapter 3 Market Variables, Trends & Scope
                    3.1 Market Segmentation & Scope
                         3.1.1 Market driver analysis
                               3.1.1.1 Increasing number of market players
                               3.1.1.2 Increasing application of doxorubicin
                               3.1.1.3 Growing number of cancer cases
                         3.1.2 Market restraint analysis
                               3.1.2.1 Supply demand gap
                    3.2 Penetration & Growth Prospect Mapping
                    3.3 Doxorubicin Market- SWOT Analysis, by Factor (Political &Legal, Economic, and Technological)
                    3.4 Industry Analysis - Porter’s
Chapter 4 Market Categorization 1: Application Estimates & Trend Analysis
                    4.1 Doxorubicin Market: ApplicationMovement Analysis
                    4.2 Ovarian Cancer
                         4.2.1 Ovarian cancer market estimates and forecasts, 2013 - 2024 (USD Million)
                    4.3 Multiple Myeloma
                         4.3.1 Multiple myeloma market estimates and forecasts, 2013 - 2024 (USD Million)
                    4.4 Kaposi Sarcoma
                         4.4.1 Kaposi Sarcoma market estimates and forecasts, 2013 - 2024 (USD Million)
                    4.5 Leukemia
                         4.5.1 Leukemia market estimates and forecasts, 2013 - 2024 (USD Million)
                    4.6 Bone sarcoma
                         4.6.1 Bone sarcoma market estimates and forecasts, 2013 - 2024 (USD Million)
                    4.7 Breast cancer
                         4.7.1 Breast cancer market estimates and forecasts, 2013 - 2024 (USD Million)
                    4.8 Endometrial cancer
                         4.8.1 Endometrial cancer market estimates and forecasts, 2013 - 2024 (USD Million)
                    4.9 Gastric cancer
                         4.9.1 Gastric cancer market estimates and forecasts, 2013 - 2024 (USD Million)
                    4.10 Liver cancer
                         4.10.1 Liver cancer market estimates and forecasts, 2013 - 2024 (USD Million)
                    4.11 Kidney cancer
                         4.11.1 Kidney cancer market estimates and forecasts, 2013 - 2024 (USD Million)
                    4.12 Other cancer
                         4.12.1 Other cancer market estimates and forecasts, 2013 - 2024 (USD Million)
Chapter 5 Market Categorization 4: Regional Estimates & Trend Analysis
                    5.1 Doxorubicin Market Share by Region, 2013 & 2024
                    5.2 North America
                         5.2.1 North America doxorubicin market estimates and forecasts, by application 2013 - 2024(USD Million)
                         5.2.2 The U.S.
                               5.2.2.1 U.S. doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
                         5.2.3 Canada
                               5.2.3.1 Canada doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
                    5.3 Europe
                         5.3.1 Europe doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
                         5.3.2 Germany
                               5.3.2.1 Germany doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
                         5.3.3 UK
                               5.3.3.1 UK doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
                    5.4 Asia Pacific
                         5.4.1 Asia Pacific doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
                         5.4.2 Japan
                               5.4.2.1 Japan doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
                         5.4.3 China
                               5.4.3.1 China doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
                    5.5 Latin America
                         5.5.1 Latin America doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
                         5.5.2 Brazil
                               5.5.2.1 Brazil doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
                         5.5.3 Mexico
                               5.5.3.1 Mexico doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
                    5.6 MEA
                         5.6.1 MEA doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
                         5.6.2 South Africa
                               5.6.2.1 South Africa doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
Chapter 6 Competitive Landscape
                    6.1 Strategy Framework
                    6.2 Market Participation Categorization
                    6.3 Company Profiles
                         6.3.1 Pfizer, Inc.
                               6.3.1.1 Company overview
                               6.3.1.2 Financial performance
                               6.3.1.3 Product benchmarking
                               6.3.1.4 Strategic initiatives
                         6.3.2 Sun Pharmaceutical Industries Ltd.
                               6.3.2.1 Company overview
                               6.3.2.2 Financial performance
                               6.3.2.3 Product benchmarking
                               6.3.2.4 Strategic initiatives
                         6.3.3 Cipla, Inc.
                               6.3.3.1 Company overview
                               6.3.3.2 Financial performance
                               6.3.3.3 Product benchmarking
                               6.3.3.4 Strategic initiatives
                         6.3.4 Cadila Pharmaceuticals
                               6.3.4.1 Company overview
                               6.3.4.2 Financial performance
                               6.3.4.3 Product benchmarking
                               6.3.4.4 Strategic initiatives
                         6.3.5 SRS PHARMACEUTICALS PVT. LTD.
                               6.3.5.1 Company overview
                               6.3.5.2 Financial performance
                               6.3.5.3 Product benchmarking
                               6.3.5.4 Strategic initiatives
                         6.3.6 Janssen Products, LP
                               6.3.6.1 Company overview
                               6.3.6.2 Financial performance
                               6.3.6.3 Product benchmarking
                               6.3.6.4 Strategic initiatives


List of Tables

Table 1 Approved doxorubicin products, by approval date and company name
Table 2 Estimated number of cancer cases and deaths, by type in 2016
Table 3 Cancer Prevalence, by type and region in 2012
Table 4 Number of patients treated using doxorubicin, 2012
Table 5 North America doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 6 Estimated new cases of cancer, by type and age, 2015
Table 7 U.S. doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 8 Canada doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 9 Europe doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 10 UK doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 11 Germany doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 12 Asia Pacific doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 13 Number of cancer cases by site in 2015
Table 14 Japan doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 15 China doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 16 Latin America doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 17 Brazil doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 18 Mexico doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 19 MEA doxorubicin market, by application, 2013 - 2024 (USD Million)
Table 20 South Africa doxorubicin market, by application, 2013 - 2024 (USD Million)


List of Figures

FIG. 1 Market summary
FIG. 2 Market trends & outlook
FIG. 3 Market segmentation & scope
FIG. 4 Market driver relevance analysis (Current & future impact)
FIG. 5 Market restraint relevance analysis (Current & future impact)
FIG. 6 Penetration & growth prospect mapping
FIG. 7 SWOT analysis, by factor (Political & legal, economic and technological)
FIG. 8 Porter’s Five Forces Analysis
FIG. 9 Doxorubicin Market: Application outlook key takeaways
FIG. 10 Doxorubicin Market: Application movement analysis
FIG. 11 Ovarian market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 12 Multiple myeloma market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 13 Kaposi sarcoma market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 14 Leukemia market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 15 Bone sarcoma market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 16 Breast cancer market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 17 Endometrial cancer market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 18 Gastric cancer market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 19 Liver cancer market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 20 Kidney cancer market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 21 Other cancer application market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 22 Regional market place: Key takeaways
FIG. 23 Regional outlook, 2015 & 2024
FIG. 24 North America doxorubicin market estimates and forecasts,by application, 2013-2024 (USD Million)
FIG. 25 U.S. doxorubicin market estimates and forecasts, by application, 2013-2024 (USD Million)
FIG. 26 Canada doxorubicin market estimates and forecasts, by application, 2013-2024 (USD Million)
FIG. 27 Europe doxorubicin market estimates and forecasts, by application, 2013-2024 (USD Million)
FIG. 28 Germany doxorubicin market estimates and forecasts, by application, 2013-2024 (USD Million)
FIG. 29 UK doxorubicin market estimates and forecasts, by application, 2013-2024 (USD Million)
FIG. 30 Asia Pacific doxorubicin market estimates and forecasts, by application, 2013 - 2024 (USD Million)
FIG. 31 Japan doxorubicin market estimates and forecasts, by application, 2013- 2024 (USD Million)
FIG. 32 Chinadoxorubicin market estimates and forecasts, by application, 2013 - 2024 (USD Million)
FIG. 33 Latin America doxorubicin market estimates and forecasts, by application, 2013-2024 (USD Million)
FIG. 34 Brazildoxorubicin market estimates and forecasts, by application, 2013 - 2024 (USD Million)
FIG. 35 Mexico doxorubicin market estimates and forecasts,by application, 2013 - 2024 (USD Million)
FIG. 36 MEA doxorubicin market estimates and forecasts,by application 2013-2024 (USD Million)
FIG. 37 South Africa doxorubicin market estimates and forecasts,by application, 2013 - 2024 (USD Million)
FIG. 38 Strategy framework
FIG. 39 Participant categorization

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.